

BMJ Open Dismantling and personalising task-sharing psychosocial interventions for common mental disorders: a study protocol for an individual participant data component network meta-analysis

Davide Papola,^{1,2} Eirini Karyotaki ,³ Marianna Purgato ,² Marit Sijbrandij,³ Federico Tedeschi,² Pim Cuijpers ,³ Efthimiou Orestis,^{4,5} Toshi A Furukawa ,⁶ Vikram Patel ,¹ Corrado Barbul²

To cite: Papola D, Karyotaki E, Purgato M, *et al.* Dismantling and personalising task-sharing psychosocial interventions for common mental disorders: a study protocol for an individual participant data component network meta-analysis. *BMJ Open* 2023;**13**:e077037. doi:10.1136/bmjopen-2023-077037

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2023-077037>).

Received 23 June 2023
Accepted 10 October 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Davide Papola;
davide_papola@hms.harvard.edu

ABSTRACT

Introduction Common mental disorders, including depression, anxiety and related somatic health symptoms, are leading causes of disability worldwide. Especially in low-resource settings, psychosocial interventions delivered by non-specialist providers through task-sharing modalities proved to be valid options to expand access to mental healthcare. However, such interventions are usually eclectic multicomponent interventions consisting of different combinations of evidence-based therapeutic strategies. Which of these various components (or combinations thereof) are more efficacious (and for whom) to reduce common mental disorder symptomatology is yet to be substantiated by evidence.

Methods and analysis Comprehensive search was performed in electronic databases MEDLINE, Embase, PsycINFO and the Cochrane Register of Controlled Trials—CENTRAL from database inception to 15 March 2023 to systematically identify all randomised controlled trials that compared any single component or multicomponent psychosocial intervention delivered through the task-sharing modality against any active or inactive control condition in the treatment of adults suffering from common mental disorders. From these trials, individual participant data (IPD) of all measured outcomes and covariates will be collected. We will dismantle psychosocial interventions creating a taxonomy of components and then apply the IPD component network meta-analysis (IPD-cNMA) methodology to assess the efficacy of individual components (or combinations thereof) according to participant-level prognostic factors and effect modifiers.

Ethics and dissemination Ethics approval is not applicable for this study since no original data will be collected. Results from this study will be published in peer-reviewed journals and presented at relevant conferences.

INTRODUCTION

Depression and anxiety are leading sources of disability worldwide,^{1 2} with depressive disorders alone being among the leading causes of disease burden globally affecting

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ We will create a taxonomy of treatment components for task-sharing psychosocial interventions to treat common mental disorders in poor resource settings.
- ⇒ Thanks to the component network meta-analysis (cNMA) methodology, we will estimate specific incremental effect size for each component.
- ⇒ Through the individual participant data cNMA (IPD-cNMA), we will identify prognostic factors and effect modifiers for the different components.
- ⇒ IPD-cNMA is limited by the availability of individual participant data, their quality and their comprehensiveness.

246 million people and contributing to 49.4 million disability-adjusted life-years.³ Anxiety and related somatic complaints, with a global prevalence estimated at 7.3%, are also major drivers of disability.⁴ The term “common mental disorders” (CMD) is used to describe the heterogeneous presentation of depressive, anxiety and somatic symptoms in community or primary care samples.⁵ Although evidence-based psychological and social interventions for CMDs are available, they remain inaccessible for the wide majority of people living in low-resource settings, where less than 5% of people with CMDs receive minimally adequate treatment.⁶

At the roots of this huge treatment gap is the great shortage and inequitable distribution of specialised mental healthcare personnel across the mental healthcare systems globally, and the dominant role played by pharmaceutical interventions.⁷ A recent Lancet series has underscored the growing need to identify how scarce resources can be used efficiently, effectively and feasibly to implement

global mental health policies.⁸ To this account, ‘task-sharing’ of psychosocial interventions has proved to be beneficial. The WHO defines task-sharing as ‘the rational redistribution of tasks among health workforce teams’.⁹ In other words, to make more efficient use of the available human resources for healthcare delivery, specific functions are shared from highly qualified health workers to health workers with fewer qualifications and shorter training. Meta-analyses of randomised controlled trials (RCTs) showed that psychosocial interventions delivered by locally available non-specialist providers (NSPs) in community and primary care settings are effective in treating CMDs in poor resource settings.^{10–12} Further insights from a recent individual participant data (IPD) meta-analysis suggested that seven individuals need to be treated to expect one individual with a 50% reduction in baseline depressive symptoms, a proportion comparable with those of the most common antidepressant medications when administered for the treatment of depression, as compared with pill placebo.^{13 14}

However, mechanisms and predictors of response to intervention components, key for improving effectiveness and for precision medicine, are poorly understood for at least three reasons.^{15 16} First, psychosocial interventions used in the context of task-sharing are usually multicomponent; they comprise multiple, distinct and possibly interacting active psychological and/or social components. These components may include behavioural, interpersonal, cognitive, problem solving, psychoeducational strategies, as well as social work elements (ie, a range of strategies and approaches aimed at addressing individuals’ social well-being).^{17–21} The standard meta-analysis methodology is not well suited to shed light on the efficacy of each of these multiple components, as they are packed in heterogeneous combinations. Second, the detection of differences among all interventions and all intervention components through individual dismantling studies is not feasible, as it would require a huge number of randomised studies with extremely large samples. Although dismantling studies have been carried out to shed light on the efficacy of selected intervention components,²² interventions in these studies were conducted by highly skilled psychotherapists, hence it is not clear whether they are still effective when applied by NSPs through the task-sharing modality. Third, it is impossible to ascertain which intervention works best and for whom using aggregate (study-level) information, as analyses that rely on group averages can be misleading about true effects at the level of individual patients.^{23–25} Since intervention components are assumed to be important drivers of outcomes, it is key to identify which of them achieve the best outcome, and what their corresponding effect sizes are.²⁶

Aim of the study

We aim to investigate which task-shared psychosocial intervention components have the best efficacy in people suffering from CMDs, identifying the impact of

participant-level prognostic factors (baseline characteristics which predict the outcome regardless of the intervention) and effect modifiers (covariates which predict differential response to treatments) on intervention outcomes.

To achieve our goal, we will employ the ‘individual participant data component network meta-analysis’ methodology (IPD-cNMA). We plan to collect IPD from RCTs that tested the efficacy of task-shared psychosocial interventions for people suffering from CMDs and use them in the component network meta-analysis (cNMA).²⁷ In this way, we will dismantle and compare the efficacy of psychosocial intervention components while personalising research findings at the same time, to detect which types of patients may benefit more from different components, or their combinations.²⁸ The findings generated by our investigation will allow to identify the best-performing active components of task-shared psychosocial interventions in the global mental health field, and tailor interventions on the needs and preferences of individuals suffering from CMDs.

METHODS

This protocol is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) for study protocols (see online supplemental file 1).²⁹

Eligibility criteria

Types of studies

We will include any studies that allocated participants or clusters of participants by a random method to a task-shared psychosocial intervention or a control condition, or to another task-shared psychosocial intervention. We will exclude RCTs comparing psychosocial interventions against drug treatment (irrespective of drug class and dosage) and/or placebo pill. The study selection process will be reported in accordance with the PRISMA guidelines. There will be no restrictions on publication type, status, language or date.

Types of participants

We will include studies that enrolled adult participants of both sexes, aged 18–65, suffering from CMD as defined by the WHO International Classification of Diseases (ICD)-11 for ‘mental and behavioural disorders’. These categories are most likely to be used in low-resource setting service delivery: depressive disorders (ICD-11 code: 6A70–6A7Z); anxiety-related or fear-related disorders (ICD-11 codes: 6B00–6B06).³⁰ The aforementioned diagnoses will be identified either according to a diagnostic interview (eg, The Mini-International Neuropsychiatric Interview) or judged so by elevated scores at baseline on validated self-report scales measuring psychological distress (eg, the General Health Questionnaire 12), depressive (eg, Patient Health Questionnaire 9 items) or anxiety symptoms (eg, Beck Anxiety Inventory)

and level of functional impairment (eg, WHO Disability Assessment Schedule-2.0).

Comorbidities with another mental or physical disorder (eg, HIV, diabetes, hypertension) do not constitute exclusion criteria. We will exclude studies enrolling participants with severe mental disorders (such as schizophrenia, bipolar or related disorders), somatoform disorders, disorders related to substance abuse, participants with disorders specifically associated with stress (such as post-traumatic stress disorder (PTSD)), mental or behavioural disorders associated with pregnancy, childbirth or the puerperium. We will also exclude participants showing suicidal intent, or with cognitive impairment (eg, intellectual disability, dementia).

Types of interventions and comparators

We broadly conceptualise a psychosocial intervention as a non-pharmacological intervention focused on psychological or social factors or mechanisms, which contributes to an individual's mental health, well-being and social inclusion.¹⁰ We will focus on 'task-sharing' interventions, that is, interventions delivered by NSPs. These are providers who are not mental health specialists but have received some mental health training for the specific purpose of delivering the intervention.³¹ The NSP category includes community health workers, community volunteers, lay people and peers.¹¹

Consistent with the exclusion of RCTs enrolling participants subject to violence or with disorder specifically associated with stress, trauma-focused interventions will be excluded. The inclusion of people diagnosed with PTSD receiving trauma-focused interventions would create imbalances in the network both in terms of type of components and distribution of characteristic across the network comparisons, threatening the transitivity assumption.³² Stepped care as well as collaborative care interventions will be excluded as they preclude homogeneity in intervention and components administration within trial arms. We will include interventions delivered in any intervention delivery modality, such as individual in-presence, group in-presence, remote synchronous or asynchronous, guided self-help, or telephone, as long as the intervention is task-shared.³³ We will not exclude studies in which participants were allowed to take antidepressant medications, as long as the prescription is balanced across comparison groups.

The control conditions of interest will include waiting list control, no treatment control or (enhanced) treatment as usual. When no treatment or treatment as usual is used as part of the waiting list, such arms will be classified as the waiting list control at the intervention level but will be appropriately decomposed at the component level. Often in the global mental health field treatment as usual conditions are 'enhanced', as in the trial context additional actions that would not have been implemented under ordinary circumstances are pursued, mostly for ethical reasons.³⁴ In our study, treatment as usual will be defined as whatever is provided in the facility for the

Table 1 Hierarchy for the primary efficacy outcome

Hierarchy	Symptom severity rating scales	Abbreviation
1	General Health Questionnaire, 12 items	GHQ-12
2	Hospital Anxiety and Depression Scale	HADS
3	Hopkins Symptom Checklist, 25 items	HSCL-25
4	Depression Anxiety Stress Scales	DASS
5	Self-Reporting Questionnaire, 20 items	SRQ-20
6	Shona Symptom Questionnaire	SSQ-14
7	Patient Health Questionnaire, 4 items	PHQ-4
8	Brief Symptom Inventory, 18 items	BSI-18
9	Patient Health Questionnaire, 9 items	PHQ-9
10	Hamilton depression rating scale	HAMD
11	Montgomery-Asberg Depression Rating Scale	MADRS
12	Beck Depression Inventory, first or second version	BDI / BDI-II
13	Zung self-rating depression scale	Zung
14	Quick Inventory of Depressive Symptomatology	QIDS
15	Hamilton anxiety rating scale	HAMA
16	Anxiety and Related Disorders Interview Schedule	ADIS
17	Clinical Interview for Depression, anxiety subscale	CID anxiety subscale
18	Beck Anxiety Inventory	BAI
19	General Anxiety Disorder, 7 items	GAD-7
20	State-Trait Anxiety Inventory-State Version	STAI-S
21	State-Trait Anxiety Inventory-Trait Version	STAI-T
22	Zung Self-rating Anxiety Scale	ZUNG
23	Symptom Checklist-90, anxiety subscale	SCL-90 anxiety

patient's mental health condition, including conventional drug treatment either as part of the general practitioners' care or as part of the study protocol.

We will set no limits in terms of intervention duration, the number of sessions and the minimal number of participants.

Types of outcome measures

Our primary outcome will be CMD symptom reduction at study endpoint as measured on a continuous scale. Outcome scales will be prioritised according to the pragmatic outcome hierarchy depicted in table 1. If the studies use different outcome measures, they will be converted into a common metric through the equipercenile linking procedure. The equipercenile linking procedure is a statistical method used to establish a relationship between two different test scores or assessments that allows a nominal translation from one scale to another by identifying those scores on both scales that have the same percentile ranks.³⁵

Our secondary outcome will be dropout from treatment, defined as dropout from the end-of-treatment assessment for any reason as a proxy measure of treatment acceptability.

Setting

To expand access to mental healthcare a bridge needs to be built between two fields that are frequently siloed off from each other: research and implementation policies carried out in ‘low-income and middle-income countries’ (LMICs) and in ‘high-income countries’ (HICs). There is a misunderstanding regarding the fact that global mental health should be constrained to operate in LMIC, whereas compelling evidence has accumulated to suggest that task-sharing intervention delivery modality can play a substantial role in making mental healthcare better in all contexts, including within HICs.^{36–40} For this reason, studies from any country will be included.

Study identification and selection

Four bibliographical databases (MEDLINE, Embase, PsycINFO and the Cochrane Register of Controlled Trials-CENTRAL) and the International Clinical Trials Registry Platform were searched from database inception to 15 March 2023 by two independent researchers to identify RCTs suitable for inclusion according to the above-mentioned inclusion/exclusion criteria. Any disagreement will be resolved by discussion and, where necessary, in consultation with a senior author. In the search strings, we combined index terms and text words indicative of depression, anxiety, psychological distress and interventions delivered through the task-sharing modality in mental health, with filters for RCTs (see online supplemental file 2). We will also add references of trials through other sources, such as other meta-analyses and an existing database of studies on the psychological treatment of depression which served to inform the IPD of Karyotaki *et al.*^{13 41 42} We will also ask the primary authors of the eligible studies if they are aware of any other study that has been conducted in the field.

Data collection and integrity checks

Authors of the eligible studies will be contacted and requested to contribute their individual-level data. The corresponding author will be contacted first; if unreachable, a follow-up email will be sent to the senior author of the study. Reminders will be sent after 2 weeks and if necessary, after 4 weeks. If no response is received after an additional 4 weeks, the trial will be classified as ‘IPD unavailable’ and will be included in the analyses at the aggregate data level.^{43 44} Attached to the email, there will be the present study protocol. Individual-level information will include sociodemographic and clinical characteristics, primary and secondary outcome measures, date of randomisation and date of follow-ups. After gathering all primary datasets of the included trials, the data will be checked against the published reports of the trials to ensure the accuracy of the dataset. More specifically, we will check the frequencies of sociodemographic variables (eg, gender, education, marital status) as well as the mean scores of outcome scales. In case we will not be able to replicate the frequencies and means of the data reported on the published papers, we will consult

the corresponding author of the trial to clarify the reason for such discrepancies. After checking each dataset, we will merge the data into the IPD meta-analytical dataset. We will harmonise data by converting to the level of the least detailed information. For example, transformation of continuous data to a binary categorisation (ie, number of years employed into ‘employed vs unemployed’).⁴⁵ All study data will be entered in a computerised password-protected database, only accessed by named study staff and securely stored by the Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA. All study data will be used only for the purposes stated in this study protocol and will not be forwarded to third parties.

Identification of components

Two independent reviewers will classify the identified intervention and comparator trial arms and their constituent components into a taxonomy of active components. We will start by reviewing existing dismantling blueprints (ie, existing taxonomies of common psychological treatment elements and behavioural change techniques used for CMDs).^{17–21} Then, we will create the taxonomy using all available information from the publications, reviewing the intervention protocols of the identified RCTs (if available) and inquiring with the original investigators. Working in pairs, we will compile a list of eligible components and review these for duplication and redundancy. After that, each component will be operationalised and coded. Following an iterative process, similarities and discrepancies will be discussed among the coders, and the taxonomy modified accordingly. Any disagreement will be resolved by the two reviewers and, where necessary, in consultation with a senior member of the review team.

Prognostic factors and effect modifiers of intervention outcome

We will start from both study-level and individual participant-level variables. We will select candidate covariates based on previous literature findings, and depending on what will be available in the study datasets. Candidate participant-level variables based on the published literature include for example sex, age, level of education, employment, marital status, duration of current episode, prior treatments, baseline severity, baseline psychomotor symptoms, comorbid alcohol or substance abuse. Candidate study-level variables include duration of intervention and intervention delivery modality.^{13 43 46}

Risk of bias assessment

We will assess the risk of bias (ROB) in included studies using Cochrane’s second version of the ‘ROB’ tool for randomised trials (ROB 2).⁴⁷ We will assess RoB for the primary outcome at postintervention. Two review authors (DP and MP) will independently use the ROB 2 signalling questions to form judgements of material ROB for the following five domains: (1) bias arising from the randomisation process; (2) bias due to deviations from intended

interventions; (3) bias due to missing outcome data; (4) bias in the measurement of outcome and (5) bias in the selection of the reported outcome. ROB 2 allows for a judgement of overall ROB for each included study: low risk, some concerns or high risk. We will tag each study with a risk level according to the algorithm suggested by the ROB 2 tool guideline.⁴⁷ Any disagreements will be resolved by consulting with a senior author.

Missing data

In case of missing data in the IPD studies, available information at the IPD level will be used to impute the missing values; in particular, we will create multiply imputed datasets under the missing at random assumption with the *jomo* package in R.⁴⁸ This allows the imputation of either continuous or discrete, participant level or study level and systematically or sporadically missing data.⁴³

Synthesis methods

As a preliminary analysis, we will perform a conventional NMA on aggregated data to verify whether effect modifiers are evenly distributed across network comparisons, that is, verify the validity of the transitivity assumption of the network.^{43 44}

Then we will proceed to a two-step random effects network meta-analysis at the treatment level using IPD if we will obtain the datasets from all the included RCTs, otherwise using IPD studies and aggregate data. For IPD studies, we will use multiple imputations based on IPD to impute missing data (see above "missing data"),⁴⁸ for aggregate data studies we will use the published data. We will perform the network meta-analysis in a frequentist setting in R using *netmeta*,⁴⁹ assuming common heterogeneity for all treatment comparisons.⁵⁰ We will check network inconsistency, a statistical expression of intransitivity, using the back-calculation⁵¹ and the design-by-treatment methods.⁵²

If 10 or more studies will be included in a direct pairwise comparison, we will assess publication bias and small study effects by visually inspecting contour enhanced funnel plots, testing for asymmetry with the Egger's regression test.⁵³ We will assess the certainty in the body of evidence for the primary outcome through the Confidence in Network Meta-Analysis application.⁵⁴

Next, we will use cNMA models that jointly synthesise aggregate data and IPD studies.⁴³ We will perform a two-step cNMA calculating trial-level estimates of treatment effects from studies for which IPD will be available and, therefore, can be reanalysed, and published trial-level estimates from studies for which IPD will not be available. The model will assume additivity of treatment effect, that is, the total effect of each composite intervention will be assumed equal to the sum of effects of the included components⁵⁵ and examines component-covariate interactions using shrinkage methods.^{43 44 56}

For the primary outcome (continuous), we will estimate component-specific incremental mean differences to measure the added benefit of adding a component to

a psychosocial intervention. The component-covariate interactions will be modelled assuming linearity. We will repeat the procedure for the secondary outcome (binary), using a binomial likelihood, to estimate incremental ORs for each component. We will abide by the intention-to-treat (ITT) principle as far as possible, that is, we will prefer ITT to per-protocol data, but if the trial only reports per-protocol data, the latter will be used. For the dichotomous outcome, we will consider the total number of randomised participants as denominator, and where participants had been excluded from the trial before the endpoint, we will consider this a determination of a negative outcome by the end of the trial. For continuous outcomes, we will use the data as reported in the original studies.

We will use the parameter estimates to develop a web app for which the inputs are patient characteristics and two combinations of components, and the output is the estimated relative treatment effects between the two combinations.

Sensitivity analysis

- ▶ We will examine the impact of studies focusing on patients with CMDs comorbid with a physical disorder by excluding such studies from the analyses.
- ▶ A sensitivity analysis will be carried out by excluding trials judged to be at 'high ROB' to explore the putative effects of the study quality on efficacy.

ETHICS AND DISSEMINATION

The results of the present project will be published in peer-reviewed journals and disseminated electronically and in print, as well presented as abstracts and/or personal communications during national and international conferences. The present project does not involve primary data collection from humans, as it will be based on secondary analyses of already collected anonymised datasets. This study was considered exempt from review by the Harvard Longwood Campus institutional review board. However, if local ethics committees of the original research consider it necessary to have approval from the local ethics committee, we will abide by their judgements. National and international regulations on patient privacy will be followed.

Author affiliations

¹Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA

²WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Science, Section of Psychiatry, University of Verona, Verona, Italy

³Department of Clinical, Neuro and Developmental Psychology, WHO Collaborating Centre for Research and Dissemination of Psychological Interventions, Amsterdam Public Health research institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

⁴Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland

⁵Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland

⁶Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto University, Kyoto, Japan

Twitter Eirini Karyotaki @KaryotakiEirini and Toshi A Furukawa @Toshi_FRKW

Contributors DP, VP and CB conceived the study. DP drafted the protocol manuscript. EK, MP, MS, FT, PC, EO and TAF assisted in the protocol design and revision. DP, FT, CB, TAF and EO designed the statistical analysis; VP and CB are the guarantors. All authors read and approved the final version of the manuscript.

Funding This project is funded by the European Union's HORIZON EUROPE research programme under grant agreement No 101061648 to DP.

Competing interests TAF reports personal fees from Boehringer-Ingelheim, DT Axis, Kyoto University Original, Shionogi and SONY, and a grant from Shionogi, outside the submitted work. In addition, TAF has patents 2020-548587 and 2022-082495 pending, and intellectual properties for Kokoro-app licensed to Mitsubishi-Tanabe.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Eirini Karyotaki <http://orcid.org/0000-0002-0071-2599>

Marianna Purgato <http://orcid.org/0000-0002-3783-8195>

Pim Cuijpers <http://orcid.org/0000-0001-5497-2743>

Toshi A Furukawa <http://orcid.org/0000-0003-2159-3776>

Vikram Patel <http://orcid.org/0000-0003-1066-8584>

REFERENCES

- Chisholm D, Sweeny K, Sheehan P, *et al*. Scaling-up treatment of depression and anxiety: a global return on investment analysis. *Lancet Psychiatry* 2016;3:415–24.
- Vos T, Lim SS, Abbafti C, *et al*. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. *The Lancet* 2020;396:1204–22.
- Santomauro DF, Mantilla Herrera AM, Shadid J, *et al*. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *The Lancet* 2021;398:1700–12.
- Baxter AJ, Scott KM, Vos T, *et al*. Global prevalence of anxiety disorders: a systematic review and meta-regression. *Psychol Med* 2013;43:897–910.
- Goldberg D. A bio-social model for common mental disorders. *Acta Psychiatr Scand* 1994;90:66–70.
- Thornicroft G, Chatterji S, Evans-Lacko S, *et al*. Undertreatment of people with major depressive disorder in 21 countries. *Br J Psychiatry* 2017;210:119–24.
- Berwick DM. Salve Lucrum: the existential threat of greed in US health care. *JAMA* 2023;329:629–30.
- Patel V, Saxena S, Lund C, *et al*. The lancet Commission on global mental health and sustainable development. *The Lancet* 2018;392:1553–98.
- World Health Organization. *Treat train retain. Task shifting: global recommendations and guidelines*. Geneva (CH), 2008.
- Barbui C, Purgato M, Abdulmalik J, *et al*. Efficacy of Psychosocial interventions for mental health outcomes in low-income and middle-income countries: an umbrella review. *Lancet Psychiatry* 2020;7:162–72.
- van Ginneken N, Chin WY, Lim YC, *et al*. Primary-level worker interventions for the care of people living with mental disorders and distress in Low- and middle-income countries. *Cochrane Database Syst Rev* 2021;8:CD009149.
- Papola D, Purgato M, Gastaldon C, *et al*. Psychological and social interventions for the prevention of mental disorders in people living in Low- and middle-income countries affected by humanitarian crises. *Cochrane Database Syst Rev* 2020;9:CD012417.
- Karyotaki E, Araya R, Kessler RC, *et al*. Association of task-shared psychological interventions with depression outcomes in Low- and middle-income countries: a systematic review and individual patient data meta-analysis. *JAMA Psychiatry* 2022;79:430–43.
- Cipriani A, Furukawa TA, Salanti G, *et al*. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *The Lancet* 2018;391:1357–66.
- Cuijpers P, Quero S, Noma H, *et al*. Psychotherapies for depression: a network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types. *World Psychiatry* 2021;20:283–93.
- Papola D, Ostuzzi G, Tedeschi F, *et al*. Comparative efficacy and acceptability of Psychotherapies for panic disorder with or without Agoraphobia: systematic review and network meta-analysis of randomised controlled trials. *Br J Psychiatry* 2022;221:507–19.
- Chorpita BF, Becker KD, Daleiden EL. Understanding the common elements of evidence-based practice: misconceptions and clinical examples. *J Am Acad Child Adolesc Psychiatry* 2007;46:647–52.
- Chorpita BF, Daleiden EL. Mapping evidence-based treatments for children and adolescents: application of the distillation and matching model to 615 treatments from 322 randomized trials. *J Consult Clin Psychol* 2009;77:566–79.
- Michie S, Richardson M, Johnston M, *et al*. The behavior change technique Taxonomy (V1) of 93 Hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. *Ann Behav Med* 2013;46:81–95.
- Murray LK, Dorsey S, Haroz E, *et al*. A common elements treatment approach for adult mental health problems in Low- and middle-income countries. *Cogn Behav Pract* 2014;21:111–23.
- Singla DR, Kohrt BA, Murray LK, *et al*. Psychological treatments for the world: lessons from Low- and middle-income countries. *Annu Rev Clin Psychol* 2017;13:149–81.
- Cuijpers P, Cristea IA, Karyotaki E, *et al*. Component studies of psychological treatments of adult depression: A systematic review and meta-analysis. *Psychother Res* 2019;29:15–29.
- Speelman CP, McGann M. How mean is the mean? *Front Psychol* 2013;4:451.
- Heath I. How medicine has exploited rationality at the expense of humanity: an essay by Iona Heath. *BMJ* 2016;355:i5705.
- Greenhalgh T, Howick J, Maskrey N, *et al*. Evidence based medicine: a movement in crisis. *BMJ* 2014;348:g3725.
- Institute of Medicine of the National Academies. *Psychosocial interventions for mental and substance use disorders: A framework for establishing evidence-based standards*. Washington DC: National Academies Press, 2015.
- Welton NJ, Caldwell DM, Adamopoulos E, *et al*. Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease. *Am J Epidemiol* 2009;169:1158–65.
- Debray TPA, Moons KGM, van Valkenhoef G, *et al*. Get real in individual participant data (IPD) meta-analysis: a review of the methodology. *Res Synth Methods* 2015;6:293–309.
- Moher D, Shamseer L, Clarke M, *et al*. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.
- World Health Organization. International classification of diseases, 11th revision (ICD-11). n.d. Available: <https://icd.who.int>
- Patel V. The future of psychiatry in Low- and middle-income countries. *Psychol Med* 2009;39:1759–62.
- Salanti G, Del Giovane C, Chaimani A, *et al*. Evaluating the quality of evidence from a network meta-analysis. *PLoS ONE* 2014;9:e99682.
- Papola D, Ostuzzi G, Tedeschi F, *et al*. CBT treatment delivery formats for panic disorder: a systematic review and network meta-analysis of randomised controlled trials. *Psychol Med* 2023;53:614–24.
- Freedland KE, Mohr DC, Davidson KW, *et al*. Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions. *Psychosom Med* 2011;73:323–35.
- Lim RL. Linking results of distinct assessments. *Applied Measurement in Education* 1993;6:83–102.

- 36 Singla DR, Raviola G, Patel V. Scaling up psychological treatments for common mental disorders: a call to action. *World Psychiatry* 2018;17:226–7.
- 37 Singla DR, Lawson A, Kohrt BA, *et al.* Implementation and effectiveness of Nonspecialist-delivered interventions for perinatal mental health in high-income countries: A systematic review and meta-analysis. *JAMA Psychiatry* 2021;78:498–509.
- 38 Richards DA, Ekers D, McMillan D, *et al.* Cost and outcome of behavioural activation versus cognitive behavioural therapy for depression (COBRA): a randomised, controlled, non-inferiority trial. *The Lancet* 2016;388:871–80.
- 39 Thornicroft G, Deb T, Henderson C. Community mental health care worldwide: Current status and further developments. *World Psychiatry* 2016;15:276–86.
- 40 van Zyl C, Badenhorst M, Hanekom S, *et al.* “Unravelling ‘low-resource settings’: a systematic Scoping review with qualitative content analysis”. *BMJ Glob Health* 2021;6:e005190.
- 41 Cuijpers P, Miguel C, Papola D, *et al.* From living systematic reviews to meta-Analytical research domains. *Evid Based Ment Health* 2022;25:145–7.
- 42 Cuijpers P, Miguel C, Harrer M, *et al.* Psychological treatment of depression: A systematic overview of a ‘meta-analytic research domain. *J Affect Disord* 2023;335:141–51.
- 43 Furukawa TA, Sukanuma A, Ostinelli EG, *et al.* Dismantling, Optimising, and Personalising Internet cognitive behavioural therapy for depression: a systematic review and component network meta-analysis using individual participant data. *Lancet Psychiatry* 2021;8:500–11.
- 44 Furukawa TA, Karyotaki E, Sukanuma A, *et al.* Dismantling, Personalising and Optimising Internet cognitive-behavioural therapy for depression: a study protocol for individual participant data component network meta-analysis. *BMJ Open* 2019;8:bmjopen-2018-026137.
- 45 Kilpeläinen TO, Qi L, Brage S, *et al.* Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. *PLoS Med* 2011;8:e1001116.
- 46 Kessler RC, van Loo HM, Wardenaar KJ, *et al.* Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder. *Epidemiol Psychiatr Sci* 2017;26:22–36.
- 47 Sterne JAC, Savović J, Page MJ, *et al.* Rob 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;366:l4898.
- 48 Quartagno M, Carpenter JR. Substantive model compatible Multilevel multiple imputation: A joint modeling approach. *Stat Med* 2022;41:5000–15.
- 49 Balduzzi S, Rücker G, Nikolakopoulou A, *et al.* Netmeta: an R package for network meta-analysis using Frequentist methods. *J Stat Softw* 2023;106.
- 50 Efthimiou O, Debray TPA, van Valkenhoef G, *et al.* Getreal in network meta-analysis: a review of the methodology. *Res Synth Methods* 2016;7:236–63.
- 51 König J, Krahn U, Binder H. Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons. *Stat Med* 2013;32:5414–29.
- 52 White IR, Barrett JK, Jackson D, *et al.* Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. *Res Synth Methods* 2012;3:111–25.
- 53 Egger M, Davey Smith G, Schneider M, *et al.* Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.
- 54 Nikolakopoulou A, Higgins JPT, Papakonstantinou T, *et al.* Cinema: an approach for assessing confidence in the results of a network meta-analysis. *PLoS Med* 2020;17:e1003082.
- 55 Petropoulou M, Efthimiou O, Rücker G, *et al.* A review of methods for addressing components of interventions in meta-analysis. *PLoS ONE* 2021;16:e0246631.
- 56 Seo M, White IR, Furukawa TA, *et al.* Comparing methods for estimating patient-specific treatment effects in individual patient data meta-analysis. *Stat Med* 2021;40:1553–73.

SUPPLEMENTARY MATERIAL 1

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist

Section and topic	Item No	Checklist item	Page
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	N/A
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	13
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	13
Sponsor	5b	Provide name for the review funder and/or sponsor	13
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	13
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	4,5
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	5
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	5,6
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	8,9

Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	Suppl Material 2
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	9
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	9
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	9
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	9
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	7,8
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	10
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	11,12
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	11,12
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	12
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	N/A
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	11
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	11

SUPPLEMENTARY MATERIAL 2

SEARCH STRATEGY

Medline, EMBASE, PsychInfo (through OVID)

- 1 common mental disorder*/
- 2 depression/
- 3 (mental health* or mental* ill* or mental* disorder* or mental* well*).ti,ab,kf.
- 4 (depressi* adj2 (sign* or symptom* or disorder?)).ti,ab,kf.
- 5 anxiety/
- 6 ((dissociative adj3 (disorder* or reaction*)) or dissociation).ti,ab,kf.
- 7 ((mental or psychological or emotional or psycho-social or psychosocial) adj (stress* or distress*)).ti,ab,kf.
- 8 ((sub-syndrom* or sub-threshold or sub-clinical or subsyndrom* or subthreshold or subclinical or minor or brief) adj (symptom* or disorder* or condition* or depress* or anxiety)).ti,ab,kf.
- 9 (anxiety disorder? or agoraphobi* or general* anxi* or separation anxiety or neurocirculatory asthenia or neurotic disorder? or social phobi* or self-harm* or self-injur* or suicid*).ti,ab,kf.
- 10 primary health care/
- 11 physicians, family/
- 12 physicians, primary care/
- 13 general practitioners/
- 14 general practice/
- 15 family practice/
- 16 exp social support/
- 17 community health workers/
- 18 allied health personnel/
- 19 exp community health services/
- 20 rural health/
- 21 rural population/
- 22 nurses, community health/
- 23 nurses, public health/
- 24 family nursing/
- 25 primary care nursing/
- 26 rural nursing/
- 27 community health nursing/
- 28 (family practi* or family doctor* or family physician* or gp* or general practi*).ti,ab,kf.
- 29 (primary adj5 (care or health*)).ti,ab,kf.
- 30 (non-specialist* or nonspecialist* or social worker* or trainer?).ti,ab,kf.
- 31 (psycho-social or psychosocial).ti,ab,kf.
- 32 (caregiver* or care giver? or layperson*).ti,ab,kf.
- 33 (lay adj2 (heal* or person* or counsellor? or counselor? or worker? or therapist?)).ti,ab,kf.
- 34 (paraprofessional? or para-professional? or ((allied health* adj (professional? or person* or sta) or worker?)).ti,ab,kf.
- 35 (midwife or midwife* or pharmacist* or pharmacy or pharmacies or practice nurs* or district nurs* or health visitor?).ti,ab,kf.
- 36 developing Countries.sh,kf.
- 37 developed Countries.sh,kf.
- 38 (Africa or Asia or Caribbean or West Indies or South America or Latin America or Central America).hw,kf,ti,ab,cp.
- 39 (australia or japan or north America or europe or united kingdom).hw,kf,ti,ab.
- 40 (Afghanistan or Albania or Algeria or Angola or Antigua or Barbuda or Argentina or Armenia or Armenian or Aruba or Azerbaijan or Bahrain or Bangladesh or Barbados or Benin or Byelarus or Byelorussian or Belarus or Belorussian or Belorussia or Belize or Bhutan or Bolivia or Bosnia or Herzegovina or Hercegovina or Botswana or Brasil or Brazil or Bulgaria or Burkina Faso or Burkina Fasso or Upper Volta or Burundi or Urundi or Cambodia or Khmer Republic or Kampuchea or Cameroon or Cameroons or Cameron or Camerons or Cape Verde or Central African Republic or Chad or Chile or China or Colombia or Comoros or Comoro Islands or Comores or Mayotte or Congo or Zaire or Costa Rica or Cote d'Ivoire or Ivory Coast or Croatia or Cuba or Cyprus or Czechoslovakia or Czech Republic or Slovakia or Slovak Republic or Djibouti or French Somaliland

or Dominica or Dominican Republic or East Timor or East Timor or Timor Leste or Ecuador or Egypt or United Arab Republic or El Salvador or Eritrea or Estonia or Ethiopia or Fiji or Gabon or Gabonese Republic or Gambia or Gaza or Georgia Republic or Georgian Republic or Ghana or Gold Coast or Greece or Grenada or Guatemala or Guinea or Guam or Guiana or Guyana or Haiti or Honduras or Hungary or India or Maldives or Indonesia or Iran or Iraq or Isle of Man or Jamaica or Jordan or Kazakhstan or Kazakh or Kenya or Kiribati or Korea or Kosovo or Kyrgyzstan or Kirghizia or Kyrgyz Republic or Kirghiz or Kirgizstan or Lao PDR or Laos or Latvia or Lebanon or Lesotho or Basutoland or Liberia or Libya or Lithuania or Macedonia or Madagascar or Malagasy Republic or Malaysia or Malaya or Malay or Sabah or Sarawak or Malawi or Nyasaland or Mali or Malta or Marshall Islands or Mauritania or Mauritius or Agalega Islands or Mexico or Micronesia or Middle East or Moldova or Moldavia or Moldovian or Mongolia or Montenegro or Morocco or Ifni or Mozambique or Myanmar or Myanma or Burma or Namibia or Nepal or Netherlands Antilles or New Caledonia or Nicaragua or Niger or Nigeria or Northern Mariana Islands or Oman or Muscat or Pakistan or Palau or Palestine or Panama or Paraguay or Peru or Philippines or Philipines or Phillipines or Poland or Portugal or Puerto Rico or Romania or Rumania or Roumania or Russia or Russian or Rwanda or Ruanda or Saint Kitts or St Kitts or Nevis or Saint Lucia or St Lucia or Saint Vincent or St Vincent or Grenadines or Samoa or Samoan Islands or Navigator Island or Navigator Islands or Sao Tome or Saudi Arabia or Senegal or Serbia or Montenegro or Seychelles or Sierra Leone or Slovenia or Sri Lanka or Ceylon or Solomon Islands or Somalia or South Africa or Sudan or Suriname or Surinam or Swaziland or Syria or Tajikistan or Tadjhikistan or Tadjikistan or Tadzhhik or Tadzhhik or Thailand or Togo or Togolese Republic or Tonga or Trinidad or Tobago or Tunisia or Turkey or Turkmenistan or Turkmen or Uganda or Ukraine or Uruguay or USSR or Soviet Union or Union of Soviet Socialist Republics or Uzbekistan or Uzbek or Vanuatu or New Hebrides or Venezuela or Vietnam or Viet Nam or West Bank or Yemen or Yugoslavia or Zambia or Zimbabwe or Rhodesia or Andorra or Gibraltar or Panama or Greece or Poland or Aruba or Greenland or Portugal or Australia or Guam or Puerto Rico or Austria or Hong Kong or Qatar or Bahamas or Hungary or Romania or Bahrain or Iceland or Ireland or Belgium or San Marino or Bermuda or Israel or Saudi Arabia or Italy or Seychelles or Brunei or Japan or Singapore or Canada or Kuwait or Sint Maarten or Cayman Islands or Latvia or Slovakia or Liechtenstein or Slovenia or Chile or Lithuania or South Korea or Croatia or Luxembourg or Spain or Curacao or Macau or Sweden or Cyprus or Malta or Switzerland or Czech Republic or Taiwan or Denmark or Nauru or Trinidad or Tobago or Estonia or Netherlands or New Caledonia or United Arab Emirates or Finland or New Zealand or United Kingdom or France or United States or United States of America or America French Polynesia or Norway or Germany or Oman or Uruguay).hw,kf,ti,ab,cp.

- 41 ((developing or less* developed or under developed or underdeveloped or middle income or low* income or underserved or under served or deprived or poor*) adj (countr* or nation? or population? or world)).ti,ab,kf.
- 42 ((developing or less* developed or under developed or underdeveloped or middle income or low* income) adj (economy or economies)).ti,ab,kf.
- 43 ((developed or high income or industrialized or rich*) adj (countr* or nation? or population? or world)).ti,ab,kf.
- 44 ((developed or high income or industrialized or industrialized or wealthy or rich*) adj (economy or economies)).ti,ab,kf.
- 45 (low adj3 middle adj3 countr*).ti,ab,kf.
- 46 (high* adj (gdp or gnp or gross domestic or gross national)).ti,ab,kf.
- 47 (high adj3 countr*).ti,ab,kf.
- 48 or/1-9
- 49 or/10-35
- 50 or/36-47
- 51 48 and 49 and 50
- 52 exp randomized controlled trial/
- 53 controlled clinical trial.pt.
- 54 randomi#ed.ti,ab.
- 55 randomly.ti,ab.
- 56 Clinical Trials as topic.sh.
- 57 trial.ti.
- 58 or/52-57
- 59 exp animals/ not humans/
- 60 58 not 59
- 61 51 and 60

Cochrane library

ID	Search	Hits
#1	(common mental disorder*):ti,ab,kw	
#2	([mh "mental disorders"]):ti,ab,kw (Word variations have been searched)	
#3	[mh "mental health"]	
#4	[mh "depression"]	
#5	(mental next health* or mental* next ill* or mental* next disorder* or mental* next well*):ti,ab	
#6	(depressi* near/2 (sign* or symptom* or disorder*)):ti,ab	
#7	((dissociative near/3 (disorder* or reaction*)) or dissociation):ti,ab	
#8	((mental or psychological or emotional or (psycho next social) or psychosocial) next (stress* or distress*)):ti,ab	
#9	((sub-syndrom* or sub-threshold or sub-clinical or subsyndrom* or subthreshold or subclinical or minor or brief) next (symptom* or disorder* or condition* or depress* or anxiety)):ti,ab	
#10	("mental relapse" or fatigue or (somatic next symptom?) or worry or worries or panic or (low next mood?) or (mood next problem?)):ti,ab	
#11	((anxiety next disorder?) or agoraphobi* or (general* next anxi*) or "separation anxiety" or "neurocirculatory asthenia" or (neurotic next disorder?) or (social next phobi*) or (self next harm*) or (self next injur*) or suicid*):ti,ab	
#12	{or #1-#11}	
#13	[mh "primary health care"]	
#14	[mh "physicians, family"]	
#15	[mh "physicians, primary care"]	
#16	[mh "general practitioners"]	
#17	[mh "general practice"]	
#18	[mh "family practice"]	
#19	[mh "social support"]	
#20	[mh "community health workers"]	
#21	[mh "allied health personnel"]	
#22	[mh "community health services"]	
#23	[mh "rural health"]	
#24	[mh "rural population"]	
#25	[mh "nurses, community health"]	
#26	[mh "nurses, public health"]	
#27	[mh "primary care nursing"]	
#28	[mh "community health nursing"]	

- #29 (primary near/5 (care or health*)):ti,ab
- #30 ((family next practi*) or (family next doctor*) or (family next physician*) or gp* or (general next practi*)):ti,ab
- #31 ((non next specialist*) or nonspecialist* or (social next worker*) or trainer?):ti,ab
- #32 (psycho next social or psychosocial):ti,ab
- #33 (caregiver* or (care next giver?) or layperson*):ti,ab
- #34 (paraprofessional* or (para next professional*) or (non next physician?) or (non next clinician?)):ti,ab
- #35 (allied near/2 (professional? or person* or staff or worker?)):ti,ab
- #36 (lay near/2 (heal* or person* or counsellor? or counselor? or worker? or therapist?)):ti,ab
- #37 (midwife or midwife* or pharmacist* or pharmacy or pharmacies or (practice next nurs*) or (district next nurs*) or (health next visitor?)):ti,ab
- #38 {or #13-#37}
- #39 #12 and #38
- #40 [mh “developing countries”]
- #41 (africa or asia or caribbean or “west indies” or “south America” or “latin America” or “central America” or australia or japan or north America or europe or united kingdom):ti,ab,kw
- #42 (afghanistan or albania or algeria or angola or antigua or barbuda or argentina or armenia or armenian or aruba or azerbaijan or bahrain or bangladesh or barbados or benin or byelarus or byelorussian or belarus or belorussian or belorussia or belize or bhutan or bolivia or bosnia or herzegovina or hercegovina or botswana or brasil or brazil or bulgaria or “burkina faso” or “burkina fasso” or “upper volta” or burundi or urundi or cambodia or “khmer republic” or kampuchea or cameroon or cameroons or cameron or camérons or “cape verde” or “central african republic” or chad or chile or china or colombia or comoros or “comoro islands” or comores or mayotte or congo or zaire or “costa rica” or “cote d’ivoire” or “ivory coast” or croatia or cuba or cyprus or czechoslovakia or “czech republic” or slovakia or “slovak republic” or djibouti or “french Somaliland” or dominica or “dominican republic” or “east timor” or “east timur” or “timor leste” or ecuador or egypt or “united arab republic” or “el Salvador” or eritrea or estonia or ethiopia or fiji or gabon or “gabonese republic” or gambia or gaza or “georgia republic” or “georgian republic” or ghana or “gold coast” or greece or grenada or guatemala or guinea or guam or guiana or guyana or haiti or honduras or hungary or india or maldives or indonesia or iran or iraq or “isle of man” or jamaica or jordan or kazakhstan or kazakh or kenya or kiribati or korea or kosovo or kyrgyzstan or kirghizia or “kyrgyz republic” or kirghiz or kirgizstan or “lao pdr” or laos or latvia or lebanon or lesotho or basutoland or liberia or libya or lithuania or macedonia or madagascar or “malagasy republic” or malaysia or malaya or malay or sabah or sarawak or malawi or niasaland or mali or malta or “marshall islands” or mauritania or mauritius or “agalega islands” or mexico or micronesia or “middle east” or moldova or moldovia or moldovian or mongolia or montenegro or morocco or ifni or mozambique or myanmar or myanma or burma or namibia or nepal or “netherlands Antilles” or “new caledonia” or nicaragua or niger or nigeria or “northern mariana islands” or oman or muscat or pakistan or palau or palestine or panama or paraguay or peru or philippines or philippines or phillippines or poland or portugal or “puerto rico” or romania or rumania or roumania or russia or russian or rwanda or ruanda or “saint kitts” or “st kitts” or nevis or “saint lucia” or “st lucia” or “saint vincent” or “st vincent” or grenadines or samoa or “samoan islands” or “navigator island” or “navigator islands” or “sao tome” or “saudi arabia” or senegal or serbia or montenegro or seychelles or “sierra leone” or slovenia or “sri lanka” or ceylon or “solomon islands” or somalia or “south Africa” or sudan or suriname or surinam or swaziland or syria or tajikistan or tadjikistan or tadjik or tanzania or thailand or togo or “togolese republic” or tonga or trinidad or tobago or tunisia or turkey or turkmenistan or turkmen or uganda or ukraine or uruguay or ussr or “soviet union” or “union of soviet socialist republics” or uzbekistan or uzbek or vanuatu or “new Hebrides” or venezuela or vietnam or “viet nam” or “west bank” or yemen or yugoslavia or zambia or zimbabwe or Rhodesia or Andorra or Gibraltar or Panama or Greece or Poland or Aruba or Greenland or Portugal or Australia or Guam or Puerto Rico or Austria or Hong Kong or Qatar or Bahamas or Hungary or Romania or Bahrain or Iceland or Ireland or Belgium or San Marino or Bermuda or Israel or Saudi Arabia or Italy or Seychelles or Brunei or Japan or Singapore or Canada or Kuwait or Sint Maarten or Cayman Islands or Latvia or Slovakia or Liechtenstein or Slovenia or Chile or Lithuania or South Korea or Croatia or Luxembourg or Spain or Curacao or Macau or Sweden or Cyprus or Malta or Switzerland or Czech Republic or Taiwan

or Denmark or Nauru or Trinidad or Tobago or Estonia or Netherlands or New Caledonia or United Arab Emirates or Finland or New Zealand or United Kingdom or France or United States or United States of America or America French Polynesia or Norway or Germany or Oman or Uruguay):ti,ab,kw

#43 ((developing or less* next developed or under next developed or underdeveloped or middle next income or low* next income or underserved or under next served or deprived or poor*) next (countr* or nation? or population? or world)):ti,ab,kw

#44 ((developing or less* next developed or under next developed or underdeveloped or middle next income or low* next income) next (economy or economies)):ti,ab,kw

#45 (low* next (gdp or gnp or “gross domestic” or “gross national”)):ti,ab,kw

#46 (low near/3 middle near/3 countr*):ti,ab,kw

#47 (lmic or lmics or “third world” or lami next countr*):ti,ab,kw

#48 (transitional next countr*):ti,ab,kw

#49 {or #40-#48}

#50 #12 and #39 and #49 in Trials